Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 194

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils

Open access
Stegh, Alexander H · 2012 · Expert Opinion on Therapeutic Targets

Abstract

INTRODUCTION: Research over the past three decades has identified p53 as a multi-functional transcription factor. p53 influences myriad, highly diverse cellular processes, and represents one of the most important and extensively studied tumor suppressors. Activated by various stresses, p53 blocks cancer progression by provoking transient or permanent growth arrest, by enabling DNA repair, or by advancing cellular death programs. This anti-cancer activity profile, together with genomic and mutational analyses documenting inactivation of p53 in more than 50% of human cancers, motivated drug development efforts to (re-) activate p53 in established tumors. AREAS COVERED: The complexities of p53 signaling in cancer are summarized, including current strategies and challenges to restore p53's tumor suppressive function in established tumors, to inactivate p53 inhibitors, and to restore wild type function of p53 mutant proteins. EXPERT OPINION: p53 represents an attractive target for the development of anti-cancer therapies. Whether p53 is 'druggable', however, remains an area of active research and discussion, as p53 has pro-survival functions and chronic p53 activation accelerates aging, which may compromise the long-term homeostasis of an organism. The complex biology and dual functions of p53 in cancer prevention and age-related cellular responses pose significant challenges to the development of p53-targeting cancer therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/14728222.2011.643299

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Research works printed but not linked: 134

  1. Vousden KH, 2007, Nat Rev Mol Cell Biol, 8, 275, 10.1038/nrm2147 · DOI · Paper page
  2. Lane DP, 1979, Nature, 278, 261, 10.1038/278261a0 · DOI · Paper page
  3. 10.1016/0092-8674(82)90356-7 · DOI · Paper page
  4. Scheffner M, 1990, Cell, 63, 1129, 10.1016/0092-8674(90)90409-8 · DOI · Paper page
  5. 10.1101/cshperspect.a001016 · DOI · Paper page
  6. Yonish-Rouach E, 1991, Nature, 352, 345, 10.1038/352345a0 · DOI · Paper page
  7. Clarke AR, 1993, Nature, 362, 849, 10.1038/362849a0 · DOI · Paper page
  8. Lowe SW, 1993, Cell, 74, 957, 10.1016/0092-8674(93)90719-7 · DOI · Paper page
  9. Sheikh MS, 1998, Cancer Res, 58, 1593
  10. Peter ME, 2003, Cell Death Differ, 10, 26, 10.1038/sj.cdd.4401186 · DOI · Paper page
  11. Ehrhardt H, 2008, Oncogene, 27, 783, 10.1038/sj.onc.1210666 · DOI
  12. Attardi LD, 2000, Genes Dev, 14, 704, 10.1101/gad.14.6.704 · DOI · Paper page
  13. Davies L, 2009, J Cell Mol Med, 13, 1995, 10.1111/j.1582-4934.2008.00590.x · DOI
  14. Stegh AH, 2001, Cardiol Clin, 19, 13, 10.1016/S0733-8651(05)70192-2 · DOI
  15. Youle RJ, 2008, Nat Rev Mol Cell Biol, 9, 47, 10.1038/nrm2308 · DOI · Paper page
  16. Miyashita T, 1995, Cell, 80, 293, 10.1016/0092-8674(95)90513-8 · DOI · Paper page
  17. Yu J, 2001, Mol Cell, 7, 673, 10.1016/S1097-2765(01)00213-1 · DOI · Paper page
  18. Han J, 2001, Proc Natl Acad Sci USA, 98, 11318, 10.1073/pnas.201208798 · DOI · Paper page
  19. 10.1126/science.284.5411.156 · DOI · Paper page
  20. Jeffers JR, 2003, Cancer Cell, 4, 321, 10.1016/S1535-6108(03)00244-7 · DOI · Paper page
  21. Chipuk JE, 2003, Cancer Cell, 4, 371, 10.1016/S1535-6108(03)00272-1 · DOI · Paper page
  22. Caelles C, 1994, Nature, 370, 220, 10.1038/370220a0 · DOI · Paper page
  23. Johnson TM, 2008, Proc Natl Acad Sci USA, 105, 1215, 10.1073/pnas.0706764105 · DOI
  24. Chipuk JE, 2005, Science, 309, 1732, 10.1126/science.1114297 · DOI · Paper page
  25. Mihara M, 2003, Mol Cell, 11, 577, 10.1016/S1097-2765(03)00050-9 · DOI · Paper page
  26. Leu JI, 2004, Nat Cell Biol, 6, 443, 10.1038/ncb1123 · DOI · Paper page
  27. 10.4161/cc.7.18.6759 · DOI
  28. Stegh AH, 2008, Proc Natl Acad Sci USA, 105, 10703, 10.1073/pnas.0712034105 · DOI
  29. Stegh AH, 2007, Genes Dev, 21, 98, 10.1101/gad.1480007 · DOI
  30. Stegh AH, 2010, Genes Dev, 24, 2194, 10.1101/gad.1924710 · DOI
  31. 10.4161/cc.10.1.14365 · DOI
  32. Kumar S, 2009, Nat Rev Cancer, 9, 897, 10.1038/nrc2745 · DOI
  33. Tinel A, 2004, Science, 304, 843, 10.1126/science.1095432 · DOI · Paper page
  34. Lin Y, 2000, Nat Genet, 26, 122, 10.1038/79102 · DOI · Paper page
  35. Zong WX, 2006, Genes Dev, 20, 1, 10.1101/gad.1376506 · DOI · Paper page
  36. Yuan J, 2010, Genes Dev, 24, 2592, 10.1101/gad.1984410 · DOI · Paper page
  37. Tu HC, 2009, Proc Natl Acad Sci USA, 106, 1093, 10.1073/pnas.0808173106 · DOI
  38. Giono LE, 2006, J Cell Physiol, 209, 13, 10.1002/jcp.20689 · DOI · Paper page
  39. Sherr CJ, 1994, Cell, 79, 551, 10.1016/0092-8674(94)90540-1 · DOI · Paper page
  40. el-Deiry WS, 1994, Cancer Res, 54, 1169
  41. el-Deiry WS, 1993, Cell, 75, 817, 10.1016/0092-8674(93)90500-P · DOI · Paper page
  42. Waldman T, 1995, Cancer Res, 55, 5187
  43. Rohaly G, 2005, Cell, 122, 21, 10.1016/j.cell.2005.04.032 · DOI
  44. St Clair S, 2004, Mol Cell, 16, 725, 10.1016/j.molcel.2004.11.002 · DOI · Paper page
  45. Hermeking H, 1997, Mol Cell, 1, 3, 10.1016/S1097-2765(00)80002-7 · DOI · Paper page
  46. Ando T, 2001, J Biol Chem, 276, 42971, 10.1074/jbc.M106460200 · DOI · Paper page
  47. Zhan Q, 1999, Oncogene, 18, 2892, 10.1038/sj.onc.1202667 · DOI · Paper page
  48. Jin S, 2000, J Biol Chem, 275, 16602, 10.1074/jbc.M000284200 · DOI · Paper page
  49. Nezi L, 2009, Curr Opin Cell Biol, 21, 785, 10.1016/j.ceb.2009.09.007 · DOI · Paper page
  50. Cross SM, 1995, Science, 267, 1353, 10.1126/science.7871434 · DOI · Paper page
  51. Di Leonardo A, 1997, Cancer Res, 57, 1013
  52. Fukasawa K, 1996, Science, 271, 1744, 10.1126/science.271.5256.1744 · DOI · Paper page
  53. 10.1128/MCB.18.2.1055 · DOI · Paper page
  54. Smith ML, 1994, Science, 266, 1376, 10.1126/science.7973727 · DOI · Paper page
  55. Smith ML, 1996, Oncogene, 13, 2255
  56. Janus F, 1999, Cell Mol Life Sci, 55, 12, 10.1007/s000180050266 · DOI
  57. Gottlieb E, 2010, Cold Spring Harb Perspect Biol, 2, a001040, 10.1101/cshperspect.a001040 · DOI · Paper page
  58. Ma W, 2007, J Bioenerg Biomembr, 39, 243, 10.1007/s10863-007-9083-0 · DOI
  59. Kulawiec M, 2009, J Carcinog, 8, 8, 10.4103/1477-3163.50893 · DOI
  60. Lebedeva MA, 2009, Biochim Biophys Acta, 1787, 328, 10.1016/j.bbabio.2009.01.004 · DOI · Paper page
  61. Okamura S, 1999, Oncol Res, 11, 281
  62. Schwartzenberg-Bar-Yoseph F, 2004, Cancer Res, 64, 2627, 10.1158/0008-5472.CAN-03-0846 · DOI · Paper page
  63. Kawauchi K, 2008, Nat Cell Biol, 10, 611, 10.1038/ncb1724 · DOI · Paper page
  64. Bensaad K, 2007, Trends Cell Biol, 17, 286, 10.1016/j.tcb.2007.04.004 · DOI · Paper page
  65. Li H, 2009, J Biol Chem, 284, 1748, 10.1074/jbc.M807821200 · DOI
  66. Vousden KH, 2009, Biochem Soc Trans, 37, 511, 10.1042/BST0370511 · DOI
  67. Muniyappa H, 2009, J Biol Chem, 284, 17069, 10.1074/jbc.M109.008557 · DOI
  68. Budanov AV, 2004, Science, 304, 596, 10.1126/science.1095569 · DOI · Paper page
  69. Cano CE, 2009, Cancer Res, 69, 219, 10.1158/0008-5472.CAN-08-2320 · DOI
  70. Hayflick L, 1965, Exp Cell Res, 37, 614, 10.1016/0014-4827(65)90211-9 · DOI · Paper page
  71. Zilfou JT, 2009, Cold Spring Harb Perspect Biol, 1, a001883, 10.1101/cshperspect.a001883 · DOI · Paper page
  72. Gorgoulis VG, 2003, EMBO J, 22, 1567, 10.1093/emboj/cdg157 · DOI
  73. Dumble M, 2007, Blood, 109, 1736, 10.1182/blood-2006-03-010413 · DOI · Paper page
  74. Junttila MR, 2010, Nature, 468, 567, 10.1038/nature09526 · DOI · Paper page
  75. Feldser DM, 2010, Nature, 468, 572, 10.1038/nature09535 · DOI · Paper page
  76. 10.1093/carcin/23.12.2011 · DOI · Paper page
  77. 10.1002/(SICI)1097-0215(19960917)67:6<808::AID-IJC9>3.0.CO;2-V · DOI
  78. Gomez-Manzano C, 1996, Cancer Res, 56, 694
  79. Gomez-Manzano C, 1997, J Natl Cancer Inst, 89, 1036, 10.1093/jnci/89.14.1036 · DOI
  80. 10.1097/00006123-199911000-00016 · DOI
  81. Li H, 1999, Clin Cancer Res, 5, 637
  82. Lang FF, 2003, J Clin Oncol, 21, 2508, 10.1200/JCO.2003.11.138 · DOI · Paper page
  83. 10.1158/1078-0432.CCR-09-1044 · DOI
  84. Zeimet AG, 2003, Lancet Oncol, 4, 415, 10.1016/S1470-2045(03)01139-2 · DOI · Paper page
  85. Nemunaitis J, 2000, Cancer Res, 60, 6359
  86. Shi J, 2009, Curr Opin Mol Ther, 11, 547
  87. 10.1007/s00432-009-0701-6 · DOI
  88. Tian G, 2009, Anticancer Drugs, 20, 389, 10.1097/CAD.0b013e32832a2df9 · DOI
  89. 10.1158/1535-7163.MCT-07-0125 · DOI
  90. 10.3892/or_00001018 · DOI
  91. Pan JJ, 2009, J Clin Oncol, 27, 799, 10.1200/JCO.2008.18.9670 · DOI
  92. Li Y, 2009, Clin Cancer Res, 15, 6724, 10.1158/1078-0432.CCR-09-1296 · DOI
  93. Keedy V, 2008, J Clin Oncol, 26, 4166, 10.1200/JCO.2007.15.6927 · DOI
  94. Ulasov IV, 2007, Hum Gene Ther, 18, 118, 10.1089/hum.2006.146 · DOI
  95. Bischoff JR, 1996, Science, 274, 373, 10.1126/science.274.5286.373 · DOI · Paper page
  96. Khuri FR, 2000, Nat Med, 6, 879, 10.1038/78638 · DOI · Paper page
  97. O'Shea CC, 2004, Cancer Cell, 6, 611, 10.1016/j.ccr.2004.11.012 · DOI · Paper page
  98. Chiocca EA, 2004, Mol Ther, 10, 958, 10.1016/j.ymthe.2004.07.021 · DOI · Paper page
  99. 10.2174/156800907780058862 · DOI
  100. Tyler MA, 2009, Gene Ther, 16, 262, 10.1038/gt.2008.165 · DOI
  101. 10.1634/stemcells.2007-0758 · DOI · Paper page
  102. Sherr CJ, 2006, Nat Rev Cancer, 6, 663, 10.1038/nrc1954 · DOI · Paper page
  103. 10.4161/cc.3.4.801 · DOI · Paper page
  104. Kojima K, 2005, Blood, 106, 3150, 10.1182/blood-2005-02-0553 · DOI · Paper page
  105. Secchiero P, 2009, Blood, 113, 4300, 10.1182/blood-2008-11-187708 · DOI
  106. Carter BZ, 2010, Blood, 115, 306, 10.1182/blood-2009-03-212563 · DOI
  107. Galatin PS, 2004, J Med Chem, 47, 4163, 10.1021/jm034182u · DOI
  108. Lu Y, 2006, J Med Chem, 49, 3759, 10.1021/jm060023+ · DOI
  109. Yin H, 2005, Angew Chem Int Ed Engl, 44, 2704, 10.1002/anie.200462316 · DOI · Paper page
  110. 10.1158/1535-7163.MCT-05-0199 · DOI · Paper page
  111. Essmann F, 2011, Br J Pharmacol
  112. Hardcastle IR, 2011, J Med Chem, 54, 1233, 10.1021/jm1011929 · DOI
  113. 10.1021/jm0601194 · DOI
  114. 10.4161/cc.1.6.259 · DOI
  115. Sur S, 2009, Proc Natl Acad Sci USA, 106, 3964, 10.1073/pnas.0813333106 · DOI · Paper page
  116. 1998, Crit Rev Immunol, 18, 29, 10.1615/CritRevImmunol.v18.i1-2.40 · DOI
  117. 10.1158/1078-0432.CCR-08-2227 · DOI · Paper page
  118. 10.1038/onc.2008.249 · DOI
  119. Bykov VJ, 2005, J Biol Chem, 280, 30384, 10.1074/jbc.M501664200 · DOI · Paper page
  120. Wiman KG, 2010, Oncogene, 29, 4245, 10.1038/onc.2010.188 · DOI · Paper page
  121. Boeckler FM, 2008, Proc Natl Acad Sci USA, 105, 10360, 10.1073/pnas.0805326105 · DOI · Paper page
  122. 10.1101/sqb.2005.70.049 · DOI
  123. Demma M, 2010, J Biol Chem, 285, 10198, 10.1074/jbc.M109.083469 · DOI
  124. Kravchenko JE, 2008, Proc Natl Acad Sci USA, 105, 6302, 10.1073/pnas.0802091105 · DOI · Paper page
  125. North S, 2002, Mol Carcinog, 33, 181, 10.1002/mc.10038 · DOI
  126. Weinmann L, 2008, Cell Death Differ, 15, 718, 10.1038/sj.cdd.4402301 · DOI
  127. Belyi VA, 2010, Cold Spring Harb Perspect Biol, 2, a001198, 10.1101/cshperspect.a001198 · DOI · Paper page
  128. 10.1038/onc.2010.266 · DOI
  129. Saddler C, 2008, Blood, 111, 1584, 10.1182/blood-2007-09-112698 · DOI
  130. Calabro V, 2004, Mol Cell Biol, 24, 8529, 10.1128/MCB.24.19.8529-8540.2004 · DOI
  131. Wang H, 2011, Mol Cancer Ther, 10, 69, 10.1158/1535-7163.MCT-10-0581 · DOI · Paper page
  132. Issaeva N, 2004, Nat Med, 10, 1321, 10.1038/nm1146 · DOI · Paper page
  133. Smith MA, 2011, Pediatr Blood Cancer
  134. Bernal F, 2007, J Am Chem Soc, 129, 2456, 10.1021/ja0693587 · DOI · Paper page

Cited by

Metadata

Authors
Stegh, A. H.
Venue
Expert Opinion on Therapeutic Targets
Published
2012-01
Volume
16
Issue
1
Pages
67-83
ISSN
  • 1472-8222 (ISSN-L)
  • 1744-7631
OpenAlex
W1980250100
Cited by
194
References
59
FWCI
7.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.